Novavax Pharmaceuticals (NVAX. O) took a short dive, widening its decline to 4 percent, as the Wall Street Journal reported that the company's COVID-19 vaccine is unlikely to be approved anytime soon.
2025-04-02 16:21:28
Novavax Pharmaceuticals (NVAX. O) took a short dive, widening its decline to 4 percent, as the Wall Street Journal reported that the company's COVID-19 vaccine is unlikely to be approved anytime soon.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
